Preparing for an uncertain respiratory season
Meet the challenges that this respiratory season will bring
As COVID-19 public health measures are reduced, influenza-like illnesses (ILIs) and COVID-19 will converge this respiratory season. Many regions in the U.S. have seen interseasonal increases in common respiratory pathogens (1–3). Similar symptomology between these pathogens and SARS-CoV-2, rising cases and the high risk of co-infections will likely present exceptional challenges to healthcare systems.
Diagnostic approaches using rapid molecular testing may help alleviate this burden. The Centers for Disease Control and Prevention has recommended the use of multiplex testing while COVID-19 and the flu are co-circulating (4). Highly multiplexed testing, commonly known as syndromic testing, can detect and differentiate >20 bacterial and viral pathogens in around one hour.
Featured – explore syndromic respiratory testing
Confronting emerging COVID-19 variantsOver the course of the COVID-19 pandemic, data on novel SARS-CoV-2 variants with potentially increased transmissibility has continued to evolve Stay up to date on our continuous surveillance assessing the impact of mutations on assay sensitivity. (Updated September 2021)
COVID-19 and co-infection – what do we know?Sometimes, testing for SARS-CoV-2 is not enough. A 30-study systematic review and meta-analysis published in the Journal of Infection suggests that some COVID-19 patients may be infected by more than one pathogen.
Multiple benefits to syndromic testingTraditional diagnostic methods, such as bacterial culture and microscopy, can take too long or are not sensitive enough. View our infographic to see how the benefits of syndromic testing go beyond improved patient care and extend throughout your hospital system.
Uniquely powerful – our solution for syndromic testing
Comprehensive pathogen identificationThe QIAstat-Dx Respiratory SARS-CoV-2 Panel offers:
- Detection of 21 respiratory targets, including SARS-CoV-2
- Comprehensive results in around 1 hour
Ct values and amplification curves
The QIAstat-Dx System provides additional information that may help support diagnostic decision making:
- Ct values
- Amplification curves
Powerful connectivity features
Connection with the QIAsphere app provides*:
- QIAstat-Dx Analyzer status updates – anytime, anywhere
- Remote and proactive technical support
- On-demand epidemiological reports
COVID-19 solutions and resourcesLearn more about how QIAGEN solutions can be used in the fight against COVID-19, or get in touch to let us know how we can support your lab.
Verification guidelines for our respiratory assayIn this application note, read a sample protocol for verifying the performance of the QIAstat-Dx Respiratory SARS-CoV-2 Panel in your laboratory.
The benefits of syndromic testing extend beyond the pandemicThe team at Mako Medical in North Carolina, USA, recognizes senior living communities are especially vulnerable to disease outbreaks. Syndromic testing is used at this lab to ensure fast results.
QIAstat-Dx reporting at your fingertipsGet complete visibility of QIAstat-Dx instrument status across your institute with push notifications in the QIAsphere app. The app works in harmony with your local network to help you maximize productivity – learn more in our connectivity guide.